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apertures on a planar surface suitable for neuronal culture. Using 
synaptically connected snail neurons cultures on these chips, high 
quality recordings were obtained in both current- and voltage-
clamp. If successfully translated to mammalian neurons, this new 
technology will provide an important tool for developing and test-
ing drugs on more relevant physiological disease models (see also 
Nagarah, 2011).
The development of new technologies has increased the number 
of drugs that can be identified, synthesized, characterized, screened, 
and tested for therapeutic efficacy and safety. However, the process 
of drug discovery is long and expensive. Pharmaceuticals spend $50 
billion annually in R&D and the average cost to bring a new drug 
to the market is estimated at $1.8 billion (Paul et al., 2010). Most 
compounds fail in clinical trials, requiring development of new 
strategies, and methodologies. Kaczorowski et al. (2011) suggest 
that the profiling of putative lead compounds to identify off-target 
activities joined with medicinal chemistry research to minimize 
such activities could save valuable time and money during the pre-
clinical lead optimization phase.
Since ion channels control conduction of electrical activity in 
the heart, it is crucial to discern if off-target activities of drug can-
didates include cardiac ion channels. Möller and Witchel (2011) 
review the most recent methods to screen drug candidates in major 
cardiac ion channels. These methods include APC using heterolo-
gous expression systems and automated action potential recordings 
from stem-cell derived cardiomyocyte. Polonchuk (2012) evalu-
ates the use of a fully APC system with integrated temperature 
control – the PatchLiner (Nanion Technologies GmbH, Munich, 
Germany) – with an ether-á-go–go related gene K+ channels assay, 
in an effort to set a new standard in ion channel research for drug 
safety testing. For their part, Kaestner and Lipp (2011) describe the 
advantages of screening cardiac action potentials for drug safety 
using optical devices to reduce mechanic manipulation of the cells.
Despite the efforts from public and private research to discover 
new compounds, development of treatment options for many 
human diseases remains frustratingly slow. It is therefore crucial 
to continue to seek new therapeutic targets. G protein-coupled 
inward rectifier K+ (GIRK) channels are expressed in the brain, 
heart and skeletal muscle, and endocrine tissue. GIRK channels are 
activated via G protein-coupled receptors and regulate the electrical 
activity of neurons, cardiomyocytes, and β-pancreatic cells, making 
them an important target for new drug discovery for treatment of 
neuropathic pain, drug addition, and cardiac arrhythmias (atrial 
fibrillation). Walsh (2011) describes the development of a screening 
assay which uses pituitary and cardiac cell lines expressing GIRK 
channels combined with patch-clamp and imaging techniques to 
expand on the limited pharmacology of these channels. Raphemot 
et al. (2011) describe the use of a thallium (see Van der Heyden, 
2012 for commentary) flux-based fluorescence assay to screen a 
This issue provides a comprehensive picture of the most recent 
technological advances in the field of ion channel screening. Ion 
channels are proteins that form pores in cell membranes. They 
are involved in the control of many fundamental physiological 
processes in various tissues and alterations in their functions give 
rise to pathological conditions. Ion channels were discovered in 
the membrane of electrically excitable cells such as neurons, car-
diomyocytes, and skeletal muscle fibers and, for decades, drugs 
modulating cell excitability have been targeted by the pharmaceu-
tical industry. Ion channels also play many roles in non-excitable 
tissues. Approximately 13% of marketed drugs act on ion channels 
(Clare, 2010) and new ion channel screening technologies continue 
to be developed to discover new drugs.
Patch-clamp is the gold standard technique to record ion chan-
nel activity (Hamill et al., 1981). The costs associated with this 
technique, however, are high as a result of the need for top-quality 
equipment (e.g., anti-vibrating table, micromanipulator, micro-
scope with IR-CCD camera), highly trained personnel, and low 
throughput. Over the years, there have been attempts to build 
devices to increase throughput, notably with automated electro-
physiology systems. Such systems have revolutionized ion channel 
drug discovery by enabling the screening of numerous compounds 
on many types of ion channels and cellular models. These systems 
have also been important for safety pharmacology testing of many 
types of ion channels. These methods, however, need improve-
ments with respect to throughput, quality of the electrophysiologi-
cal recordings and the physiological cellular models used for drugs 
and safety testing.
In this issue, Stoelzle et al. (2011) review the development of new 
automated patch-clamp (APC) systems capable of recording 96 cells 
in parallel and offering 5,000 data points per day, providing a high 
throughput per experiment. The development of other important 
features such as temperature control, the ability to record action 
potentials, and the testing of drugs on more relevant physiological 
models improve the quality of results. These APC systems, however, 
can only be used with suspended cell lines transfected with the ion 
channels to be studied, thereby not allowing for the study of the pro-
cesses involved in synaptic communication. Synaptic communica-
tion is critical to information processing within neuronal networks 
– the disruption of which is at the basis of many neurodegenerative 
diseases – so better understanding of the mechanisms underlying 
synaptic function requires interrogation of pre- and post-synaptic 
activity by monitoring/manipulating trans-membrane potential or 
currents from connected neurons.
Accordingly, there is a need for devices that will be simple to 
use and lead to higher throughput while providing high quality 
recordings for both the screening of native neuronal ion channels 
and the study of neuronal networks. Py et al. (2011) describe a 
new planar patch-clamp chip in which pipettes are replaced by 
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Kir1.1 inhibitor library for antagonists of GIRK. Their finding of a 
new compound, VU573, could be useful to investigate the function 
and pharmacology of these channels.
Given the importance of identifying new therapeutic targets, the 
work of Sitzia et al. (2011) on α7 nicotinic receptors – involved in 
schizophrenia and other diseases involving cognitive impairment 
as well as in neuroprotection – and their finding of the role played 
by temperature variations in the modulation of these receptors is 
an appropriate way of concluding this overview of recent advances 
in ion channel screening.
The huge developments in the field of ion channel screening 
technologies described in this issue clearly indicate that the future 
is pointed toward the screening of drugs in more physiological 
relevant cellular models and networks.
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